Search Results

Your search for Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP matches 2 pages

Showing 1 - 2

By Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP / September 10, 2022

Bispecific Antibodies and the Dawn of a New Era in Treatment of Multiple Myeloma

“I think the biggest innovations of the 21st century will be at the intersection of biology and technology. A new era is beginning!” —Steve Jobs Relapsed and refractory multiple myeloma remains a treatment challenge. Promising responses have been demonstrated with bispecific antibodies, with a...

multiple myeloma

immunotherapy

By Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP / November 25, 2021 / 2021 ASCO Annual Meeting

High-Risk Multiple Myeloma: Combination Regimens and CAR T-Cell Therapy

“Continuous improvement is better than delayed perfection.” —Mark Twain To complement The ASCO Post’s extensive coverage of the 2021 ASCO Annual Meeting, here are several abstracts selected from the meeting proceedings focusing on novel treatments under study in high-risk multiple myeloma. For...

Apr

Today In Oncology

Search Results

Your search for Syed Ali Abutalib, MD, and Saad Z. Usmani, MD, MBA, FACP matches 2 pages

Bispecific Antibodies and the Dawn of a New Era in Treatment of Multiple Myeloma

High-Risk Multiple Myeloma: Combination Regimens and CAR T-Cell Therapy

Adjuvant Pembrolizumab in Renal Cell Carcinoma: Overall Survival in KEYNOTE-564

Combined ICI and VEGF Inhibitor Trials in Cancer Cardiovascular Eligibility Criteria and Adverse Event Reporting

Risk of T-Cell and Second Primary Malignant Neoplasms After CAR T-Cell Therapy

Lack of Research Focused on Older Adults With Cancer May Be Contributing to Disparities in Care

Breast Cancer Survivors: Relationship Satisfaction and Emotional and Physical Well-Being